CA2369923A1 - Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg - Google Patents
Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg Download PDFInfo
- Publication number
- CA2369923A1 CA2369923A1 CA002369923A CA2369923A CA2369923A1 CA 2369923 A1 CA2369923 A1 CA 2369923A1 CA 002369923 A CA002369923 A CA 002369923A CA 2369923 A CA2369923 A CA 2369923A CA 2369923 A1 CA2369923 A1 CA 2369923A1
- Authority
- CA
- Canada
- Prior art keywords
- hcg
- nicked
- hcgn
- isoforms
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000035935 pregnancy Effects 0.000 title claims abstract description 33
- 102000001708 Protein Isoforms Human genes 0.000 title claims abstract description 30
- 108010029485 Protein Isoforms Proteins 0.000 title claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 15
- 238000001514 detection method Methods 0.000 title claims description 23
- 201000011510 cancer Diseases 0.000 title description 5
- 230000002159 abnormal effect Effects 0.000 title description 4
- 230000036210 malignancy Effects 0.000 claims abstract description 9
- 238000003745 diagnosis Methods 0.000 claims description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 abstract description 110
- 102000011022 Chorionic Gonadotropin Human genes 0.000 abstract description 110
- 229940084986 human chorionic gonadotropin Drugs 0.000 abstract description 109
- 208000006332 Choriocarcinoma Diseases 0.000 abstract description 14
- 150000001720 carbohydrates Chemical group 0.000 abstract description 12
- 239000003446 ligand Substances 0.000 abstract description 7
- 210000002700 urine Anatomy 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 238000010504 bond cleavage reaction Methods 0.000 abstract description 4
- 238000013198 immunometric assay Methods 0.000 abstract description 3
- 238000005259 measurement Methods 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 description 23
- 238000003018 immunoassay Methods 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 201000010374 Down Syndrome Diseases 0.000 description 5
- 206010044688 Trisomy 21 Diseases 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000898072 Homo sapiens Calretinin Proteins 0.000 description 2
- 101000806138 Homo sapiens Dehydrogenase/reductase SDR family member 4 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000002761 liquid phase assay Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108010064245 urinary gonadotropin fragment Proteins 0.000 description 2
- 101100113588 Homo sapiens CS gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La gonadotrophine chorionique humaine (hCG) existe dans le sang et l'urine en tant que variété d'isoformes. L'une d'elles, qui contient des clivages de liaisons peptidiques à l'intérieur de sa sous unité bêta, est désignée hCG coupée (hCGn). Cette isoforme de la hCGn est plus courante dans l'urine des patients présentant certaines malignités et éventuellement dans d'autres maladies de grossesse. L'invention porte sur deux anticorps monoclonaux à une isoforme de la hCGn isolée chez un patient choriocarcinome. Deux analyses immunométriques sur site ont été élaborées à l'aide de ces anticorps, désignés B151 et B152. Le premier présente une bonne spécificité pour hCGn indépendante de la source de la hCGn, forme évacuée par des patients choriocarcinomes, ou la forme de la hCGn provenant de grossesses normales. L'autre anticorps, B152, est exceptionnellement sensible aux fractions glucidiques de hCG choriocarcinome, coupée ou non, étant donné que sa reconnaissance de ligand est fonction des différences glucidiques plutôt que des différences de liaisons peptidiques. Ces deux analyses immunométriques apportent de nouveaux outils de diagnostic fondés sur le mesurage direct de ces isoformes de la hCG.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12884599P | 1999-04-12 | 1999-04-12 | |
| US60/128,845 | 1999-04-12 | ||
| PCT/US2000/009776 WO2000061638A2 (fr) | 1999-04-12 | 2000-04-12 | Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2369923A1 true CA2369923A1 (fr) | 2000-10-19 |
Family
ID=22437271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369923A Abandoned CA2369923A1 (fr) | 1999-04-12 | 2000-04-12 | Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU4234900A (fr) |
| CA (1) | CA2369923A1 (fr) |
| WO (1) | WO2000061638A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012445A1 (fr) * | 2001-07-30 | 2003-02-13 | Quest Diagnostics Investments Incorporated | Procedes et trousses de detection des ita dans un echantillon biologique |
| WO2005095458A1 (fr) * | 2004-04-02 | 2005-10-13 | The Talwar Research Foundation | Anticorps monoclonal chimerique destine a se lier selectivement a hcg avec une haute affinite |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429018B1 (en) * | 1996-09-06 | 2002-08-06 | Yale University | Prenatal screening for Down's syndrome using hyperglycosylated gonadotropin |
| US6500627B1 (en) * | 1998-02-03 | 2002-12-31 | The Trustees Of Columbia University In The City Of New York | Methods for predicting pregnancy outcome in a subject by HCG assay |
-
2000
- 2000-04-12 CA CA002369923A patent/CA2369923A1/fr not_active Abandoned
- 2000-04-12 AU AU42349/00A patent/AU4234900A/en not_active Abandoned
- 2000-04-12 WO PCT/US2000/009776 patent/WO2000061638A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000061638A2 (fr) | 2000-10-19 |
| WO2000061638A3 (fr) | 2001-04-19 |
| AU4234900A (en) | 2000-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Birken et al. | Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG | |
| US7790403B2 (en) | Methods for predicting preganancy outcome in a subject by hCG assay | |
| CA2745932C (fr) | Methodes de prevision de l'issue d'une grossesse chez un sujet par dosage biologique de hcg | |
| Stenman et al. | Standardization of protein immunoprocedures choriogonadotropin (Cg) | |
| CA2369923A1 (fr) | Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg | |
| US7198954B1 (en) | Methods for predicting pregnancy outcome in a subject by hCG assay | |
| Iwasa et al. | Highly specific enzyme immunoassay for human chorionic gonadotropin | |
| Class et al. | Patent application title: METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY Inventors: John F. O'Connor (New Rochelle, NY, US) Galina I. Kovalevskaya (Bronx, NY, US) Steven Birken (Dumont, NJ, US) Steven Birken (Dumont, NJ, US) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |